- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 1.65 Å
- Oligo State
- homo-10-mer
- Ligands
- 10 x R9M: 3-(1,3-thiazol-2-yl)propanoic acid(Non-covalent)
- 76 x EDO: 1,2-ETHANEDIOL(Non-functional Binders)
EDO.2: 6 residues within 4Å:- Chain A: Q.33, F.36, A.37, T.147, V.150
- Chain B: N.253
Ligand excluded by PLIPEDO.3: 6 residues within 4Å:- Chain A: N.253, V.254
- Chain B: Q.33, T.147
- Ligands: R9M.1, DMS.5
Ligand excluded by PLIPEDO.4: 3 residues within 4Å:- Chain A: D.188, D.191, R.289
Ligand excluded by PLIPEDO.6: 3 residues within 4Å:- Chain A: N.279
- Chain B: V.267, S.270
Ligand excluded by PLIPEDO.7: 4 residues within 4Å:- Chain A: D.87, R.112, I.114, L.171
Ligand excluded by PLIPEDO.8: 6 residues within 4Å:- Chain A: K.217, M.218, G.219
- Chain B: R.289
- Chain F: R.287
- Chain G: G.258
Ligand excluded by PLIPEDO.9: 5 residues within 4Å:- Chain A: P.257, G.258, G.259
- Chain B: R.287, L.291
Ligand excluded by PLIPEDO.10: 5 residues within 4Å:- Chain A: Q.249, D.252, N.253
- Chain C: R.222
- Ligands: DMS.5
Ligand excluded by PLIPEDO.11: 5 residues within 4Å:- Chain A: E.153, G.180, F.181
- Chain B: R.227, Q.231
Ligand excluded by PLIPEDO.13: 6 residues within 4Å:- Chain A: N.253
- Chain B: Q.33, F.36, A.37, T.147, V.150
Ligand excluded by PLIPEDO.14: 6 residues within 4Å:- Chain A: Q.33, T.147
- Chain B: N.253, V.254
- Ligands: R9M.12, DMS.16
Ligand excluded by PLIPEDO.15: 6 residues within 4Å:- Chain A: K.238
- Chain B: K.40, A.44, V.150, V.151, R.152
Ligand excluded by PLIPEDO.17: 6 residues within 4Å:- Chain A: R.227, Q.231
- Chain B: R.152, E.153, G.180, F.181
Ligand excluded by PLIPEDO.18: 4 residues within 4Å:- Chain B: F.21, Q.22, S.23, V.47
Ligand excluded by PLIPEDO.19: 3 residues within 4Å:- Chain B: E.81, Q.84, H.85
Ligand excluded by PLIPEDO.20: 4 residues within 4Å:- Chain A: E.153, K.238
- Chain B: E.153, K.238
Ligand excluded by PLIPEDO.21: 5 residues within 4Å:- Chain B: Q.249, D.252, N.253
- Chain F: R.222
- Ligands: DMS.16
Ligand excluded by PLIPEDO.23: 5 residues within 4Å:- Chain C: Q.33, F.36, A.37, V.150
- Chain D: N.253
Ligand excluded by PLIPEDO.24: 7 residues within 4Å:- Chain C: N.253, V.254
- Chain D: Q.33, L.34, T.147
- Ligands: R9M.22, DMS.25
Ligand excluded by PLIPEDO.27: 3 residues within 4Å:- Chain C: N.279
- Chain D: V.267, S.270
Ligand excluded by PLIPEDO.28: 4 residues within 4Å:- Chain C: Q.249, D.252, N.253
- Ligands: DMS.25
Ligand excluded by PLIPEDO.29: 5 residues within 4Å:- Chain C: P.257, G.258, G.259
- Chain D: R.287, L.291
Ligand excluded by PLIPEDO.30: 6 residues within 4Å:- Chain C: R.227, Q.231
- Chain D: E.153, G.180, F.181
- Ligands: DMS.40
Ligand excluded by PLIPEDO.31: 5 residues within 4Å:- Chain C: D.87, R.112, I.114, R.139, L.171
Ligand excluded by PLIPEDO.32: 3 residues within 4Å:- Chain C: T.160, G.161, T.162
Ligand excluded by PLIPEDO.33: 3 residues within 4Å:- Chain C: G.32, Q.33, K.94
Ligand excluded by PLIPEDO.34: 3 residues within 4Å:- Chain C: D.188, D.191, R.289
Ligand excluded by PLIPEDO.36: 6 residues within 4Å:- Chain C: N.253
- Chain D: Q.33, F.36, A.37, T.147, V.150
Ligand excluded by PLIPEDO.37: 5 residues within 4Å:- Chain C: Q.33, T.147
- Chain D: N.253, V.254
- Ligands: R9M.35
Ligand excluded by PLIPEDO.38: 7 residues within 4Å:- Chain A: R.274
- Chain B: D.209, D.213
- Chain C: D.209
- Chain D: G.248, K.251, R.274
Ligand excluded by PLIPEDO.39: 6 residues within 4Å:- Chain A: S.270
- Chain D: G.271, G.272, S.275, L.276, N.279
Ligand excluded by PLIPEDO.41: 4 residues within 4Å:- Chain B: R.222
- Chain D: Q.249, D.252, N.253
Ligand excluded by PLIPEDO.42: 4 residues within 4Å:- Chain C: K.238, H.242
- Chain D: V.151, R.152
Ligand excluded by PLIPEDO.44: 5 residues within 4Å:- Chain E: Q.33, F.36, A.37, T.147, V.150
Ligand excluded by PLIPEDO.45: 6 residues within 4Å:- Chain E: N.253, V.254
- Chain J: Q.33, L.34, T.147
- Ligands: R9M.43
Ligand excluded by PLIPEDO.46: 3 residues within 4Å:- Chain E: S.270, G.271
- Chain J: L.276
Ligand excluded by PLIPEDO.47: 4 residues within 4Å:- Chain E: E.153, G.180, F.181
- Chain J: Q.231
Ligand excluded by PLIPEDO.48: 5 residues within 4Å:- Chain E: A.44, V.150, V.151, R.152
- Chain J: K.238
Ligand excluded by PLIPEDO.50: 6 residues within 4Å:- Chain F: Q.33, F.36, A.37, T.147, V.150
- Chain G: N.253
Ligand excluded by PLIPEDO.51: 6 residues within 4Å:- Chain F: N.253, V.254
- Chain G: Q.33, T.147
- Ligands: R9M.49, DMS.53
Ligand excluded by PLIPEDO.52: 3 residues within 4Å:- Chain F: D.188, D.191, R.289
Ligand excluded by PLIPEDO.54: 3 residues within 4Å:- Chain F: N.279
- Chain G: V.267, S.270
Ligand excluded by PLIPEDO.55: 4 residues within 4Å:- Chain F: D.87, R.112, I.114, L.171
Ligand excluded by PLIPEDO.56: 6 residues within 4Å:- Chain A: R.287
- Chain B: G.258
- Chain F: K.217, M.218, G.219
- Chain G: R.289
Ligand excluded by PLIPEDO.57: 5 residues within 4Å:- Chain F: P.257, G.258, G.259
- Chain G: R.287, L.291
Ligand excluded by PLIPEDO.58: 5 residues within 4Å:- Chain F: Q.249, D.252, N.253
- Chain H: R.222
- Ligands: DMS.53
Ligand excluded by PLIPEDO.59: 5 residues within 4Å:- Chain F: E.153, G.180, F.181
- Chain G: R.227, Q.231
Ligand excluded by PLIPEDO.61: 6 residues within 4Å:- Chain F: N.253
- Chain G: Q.33, F.36, A.37, T.147, V.150
Ligand excluded by PLIPEDO.62: 6 residues within 4Å:- Chain F: Q.33, T.147
- Chain G: N.253, V.254
- Ligands: R9M.60, DMS.64
Ligand excluded by PLIPEDO.63: 6 residues within 4Å:- Chain F: K.238
- Chain G: K.40, A.44, V.150, V.151, R.152
Ligand excluded by PLIPEDO.65: 6 residues within 4Å:- Chain F: R.227, Q.231
- Chain G: R.152, E.153, G.180, F.181
Ligand excluded by PLIPEDO.66: 4 residues within 4Å:- Chain G: F.21, Q.22, S.23, V.47
Ligand excluded by PLIPEDO.67: 3 residues within 4Å:- Chain G: E.81, Q.84, H.85
Ligand excluded by PLIPEDO.68: 4 residues within 4Å:- Chain F: E.153, K.238
- Chain G: E.153, K.238
Ligand excluded by PLIPEDO.69: 5 residues within 4Å:- Chain A: R.222
- Chain G: Q.249, D.252, N.253
- Ligands: DMS.64
Ligand excluded by PLIPEDO.71: 5 residues within 4Å:- Chain H: Q.33, F.36, A.37, V.150
- Chain I: N.253
Ligand excluded by PLIPEDO.72: 7 residues within 4Å:- Chain H: N.253, V.254
- Chain I: Q.33, L.34, T.147
- Ligands: R9M.70, DMS.73
Ligand excluded by PLIPEDO.75: 3 residues within 4Å:- Chain H: N.279
- Chain I: V.267, S.270
Ligand excluded by PLIPEDO.76: 4 residues within 4Å:- Chain H: Q.249, D.252, N.253
- Ligands: DMS.73
Ligand excluded by PLIPEDO.77: 5 residues within 4Å:- Chain H: P.257, G.258, G.259
- Chain I: R.287, L.291
Ligand excluded by PLIPEDO.78: 6 residues within 4Å:- Chain H: R.227, Q.231
- Chain I: E.153, G.180, F.181
- Ligands: DMS.88
Ligand excluded by PLIPEDO.79: 5 residues within 4Å:- Chain H: D.87, R.112, I.114, R.139, L.171
Ligand excluded by PLIPEDO.80: 3 residues within 4Å:- Chain H: T.160, G.161, T.162
Ligand excluded by PLIPEDO.81: 3 residues within 4Å:- Chain H: G.32, Q.33, K.94
Ligand excluded by PLIPEDO.82: 3 residues within 4Å:- Chain H: D.188, D.191, R.289
Ligand excluded by PLIPEDO.84: 6 residues within 4Å:- Chain H: N.253
- Chain I: Q.33, F.36, A.37, T.147, V.150
Ligand excluded by PLIPEDO.85: 5 residues within 4Å:- Chain H: Q.33, T.147
- Chain I: N.253, V.254
- Ligands: R9M.83
Ligand excluded by PLIPEDO.86: 7 residues within 4Å:- Chain F: R.274
- Chain G: D.209, D.213
- Chain H: D.209
- Chain I: G.248, K.251, R.274
Ligand excluded by PLIPEDO.87: 6 residues within 4Å:- Chain F: S.270
- Chain I: G.271, G.272, S.275, L.276, N.279
Ligand excluded by PLIPEDO.89: 4 residues within 4Å:- Chain G: R.222
- Chain I: Q.249, D.252, N.253
Ligand excluded by PLIPEDO.90: 4 residues within 4Å:- Chain H: K.238, H.242
- Chain I: V.151, R.152
Ligand excluded by PLIPEDO.92: 5 residues within 4Å:- Chain J: Q.33, F.36, A.37, T.147, V.150
Ligand excluded by PLIPEDO.93: 6 residues within 4Å:- Chain E: Q.33, L.34, T.147
- Chain J: N.253, V.254
- Ligands: R9M.91
Ligand excluded by PLIPEDO.94: 3 residues within 4Å:- Chain E: L.276
- Chain J: S.270, G.271
Ligand excluded by PLIPEDO.95: 4 residues within 4Å:- Chain E: Q.231
- Chain J: E.153, G.180, F.181
Ligand excluded by PLIPEDO.96: 5 residues within 4Å:- Chain E: K.238
- Chain J: A.44, V.150, V.151, R.152
Ligand excluded by PLIP- 10 x DMS: DIMETHYL SULFOXIDE(Non-functional Binders)
DMS.5: 9 residues within 4Å:- Chain A: D.252, N.253, S.255, S.256, P.257
- Chain B: Q.33, K.94
- Ligands: EDO.3, EDO.10
No protein-ligand interaction detected (PLIP)DMS.16: 8 residues within 4Å:- Chain A: K.94
- Chain B: D.252, N.253, S.255, S.256, P.257
- Ligands: EDO.14, EDO.21
1 PLIP interactions:1 interactions with chain A- Hydrogen bonds: A:K.94
DMS.25: 9 residues within 4Å:- Chain C: D.252, N.253, S.255, S.256, P.257
- Chain D: Q.33, K.94
- Ligands: EDO.24, EDO.28
No protein-ligand interaction detected (PLIP)DMS.26: 3 residues within 4Å:- Chain C: R.223, L.224
- Chain D: F.181
No protein-ligand interaction detected (PLIP)DMS.40: 5 residues within 4Å:- Chain D: R.152, S.177, S.178, G.180
- Ligands: EDO.30
1 PLIP interactions:1 interactions with chain D- Salt bridges: D:E.153
DMS.53: 9 residues within 4Å:- Chain F: D.252, N.253, S.255, S.256, P.257
- Chain G: Q.33, K.94
- Ligands: EDO.51, EDO.58
No protein-ligand interaction detected (PLIP)DMS.64: 8 residues within 4Å:- Chain F: K.94
- Chain G: D.252, N.253, S.255, S.256, P.257
- Ligands: EDO.62, EDO.69
1 PLIP interactions:1 interactions with chain F- Hydrogen bonds: F:K.94
DMS.73: 9 residues within 4Å:- Chain H: D.252, N.253, S.255, S.256, P.257
- Chain I: Q.33, K.94
- Ligands: EDO.72, EDO.76
No protein-ligand interaction detected (PLIP)DMS.74: 3 residues within 4Å:- Chain H: R.223, L.224
- Chain I: F.181
No protein-ligand interaction detected (PLIP)DMS.88: 5 residues within 4Å:- Chain I: R.152, S.177, S.178, G.180
- Ligands: EDO.78
1 PLIP interactions:1 interactions with chain I- Salt bridges: I:E.153
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Ragin-Oh, W. et al., Crystallographic fragment screening reveals new starting points for PYCR1 inhibitor design. Bioorg.Chem. (2025)
- Release Date
- 2025-10-15
- Peptides
- Isoform 3 of Pyrroline-5-carboxylate reductase 1, mitochondrial: ABCDEFGHIJ
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
BC
CD
DE
EF
AG
BH
CI
DJ
E
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 1.65 Å
- Oligo State
- homo-10-mer
- Ligands
- 10 x R9M: 3-(1,3-thiazol-2-yl)propanoic acid(Non-covalent)
- 76 x EDO: 1,2-ETHANEDIOL(Non-functional Binders)
- 10 x DMS: DIMETHYL SULFOXIDE(Non-functional Binders)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Ragin-Oh, W. et al., Crystallographic fragment screening reveals new starting points for PYCR1 inhibitor design. Bioorg.Chem. (2025)
- Release Date
- 2025-10-15
- Peptides
- Isoform 3 of Pyrroline-5-carboxylate reductase 1, mitochondrial: ABCDEFGHIJ
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
BC
CD
DE
EF
AG
BH
CI
DJ
E